Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

Markets & Finance

Needham Upgrades CV Therapeutics


Needham upgrades CV Therapeutics (CVTX) to strong buy from buy.

Analyst Mark Monane says CV Therapeutics is a buying opportunity given the abundant imminent newsflow. He says the company is developing a solid near-term and long-term strategy.

He says its ERICA Phase 3 trial data is expected in late April/early May, which if positive will lead to a supplemental New Drug application (sNDA) in the second half of the year.

Monane notes the company plans to launch a 150 person salesforce to promote Aceon in the second quarter and third quarter, allowing it to build out its salesforce in anticipation of the 2006 Ranexa launch.

He expects Phase 3 data from two trials testing Regadenoson in cardiac imaging in the third quarter and fourth quarter. He has a $30 target and sees a $6.19 2005 loss and a $3.54 2006 loss.


LIMITED-TIME OFFER SUBSCRIBE NOW
 
blog comments powered by Disqus